News & Updates

Namodenoson, an A3 adenosine receptor (A3AR) agonist, shows clinical activity against nonalcoholic fatty liver disease (NAFLD) with or without nonalcoholic steatohepatitis (NASH), according to data from a phase II study.

Type 2 diabetes (T2D) patients exposed to hydrochlorothiazide for more than 2 years appear to be at higher risk of cutaneous squamous cell carcinoma (cSCC), as reported in a recent study.

Fatty acid synthase (FASN) is commonly expressed in operable triple-negative breast cancer (TNBC) and is associated with a poor prognosis, but omeprazole can hamper FASN activity, which may potentially boost the efficacy of neoadjuvant chemotherapy, according to the results of a phase II study.

A four-drug combination that includes either empagliflozin or dapagliflozin helps keep glucose in check through 3 years for patients with type 2 diabetes (T2D), in addition to its positive effect on weight and tolerable safety profile, as shown in an open-label randomized controlled study.

In the treatment of patients with chronic hepatitis B (CHB), the novel tenofovir amibufenamide (TMF) is as good as tenofovir disoproxil fumarate (TDF) in terms of efficacy but with the advantage of better bone and renal safety, according to the results of a noninferiority trial.